Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is expected to release its earnings data before the market opens on Monday, May 12th. Analysts expect Cocrystal Pharma to post earnings of ($0.52) per share for the quarter.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.23. On average, analysts expect Cocrystal Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Cocrystal Pharma Stock Down 3.1 %
Shares of COCP opened at $1.52 on Friday. Cocrystal Pharma has a 52-week low of $1.12 and a 52-week high of $3.26. The stock has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.84. The company has a market capitalization of $15.46 million, a PE ratio of -0.82 and a beta of 2.13.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on COCP
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Read More
- Five stocks we like better than Cocrystal Pharma
- Stock Sentiment Analysis: How it Works
- Google Is Betting Big on Nuclear Reactors—Should You?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- Which Wall Street Analysts are the Most Accurate?
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.